Lipocine (NASDAQ:LPCN) Stock, Quote.Headers.trade-ideas

Lipocine

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABVC

ALGN

ASPS

ASXC

BHVN

CLBK

CROX

CTCX

EBAY

ENVX

EOLS

FEMY

FFWM

IMAX

INPX

INSG

KLAC

LIXT

LPCN

LRCX

MRSN

NOVA

NVCR

OSTK

OTLY

PRFT

SHYF

SIMO

TNET

TPIC

TREE

TTNP

ULBI

VIEW

WRNT

YELL

Gainers


	Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control.


Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Biotech

Health Care

General

Lipocine Inc (NASDAQ: LPCN) shares are trading higher after the company released topline results from a Phase 2 clinical study of LPCN 1148, an oral candidate under development for the 

Why Lipocine Stock Is Moving Higher Today?

ABST

ACVA

ADSE

AMPE

BBIG

BBLN

BFLY

BNMV

BPTS

BYND

CDRO

CLSK

CPRX

DADA

DYNT

ENTG

GFAI

GRIL

GRPN

IBRX

IMBI

INTZ

JAGX

KLXE

MANU

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MGNI

MINM

MTNB

MXCT

NEPT

ORGO

PACW

PHAR

POLA

PRPL

SBFM

SMRT

SONO

TIVC

VATE

VCIG

VYNT

ZURA

Gainers


	Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales.


Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Lipocine Inc

Press Releases

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Earnings

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Lipocine Announces FDA Labeling Changes for Testosterone Products

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

CalciMedica

Cara Therapeutics

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Dare Bioscience

Durect

Gelteq

Grace Therapeutics

Hoth Therapeutics

IGC Pharma

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lyra Therapeutics

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

ProPhase Labs

Pulmatrix

Talphera

Traws Pharma

TherapeuticsMD

VYNE Therapeutics

Alliance Global Partners

Cantor Fitzgerald

Comments

Lipocine

Lipocine (NASDAQ:LPCN) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga